Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 3, 2014, Pages 320-324

  Hradsky, Ondrej ^a   Ohem, Jan ^a   Zarubova, Kristyna ^a   Mitrova, Katarina ^a   Durilova, Marianna ^a   Kotalova, Radana ^a   Nevoral, Jiri ^a   Zemanova, Ilona ^b   Dryak, Pavel ^c   Bronsky, Jiri ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^c UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

Immunosuppressive therapy; Inflammatory bowel disease; Infliximab; Interferon release tests; Latent tuberculosis

Indexed keywords

ADALIMUMAB; ALBUMIN; AZATHIOPRINE; CORTICOSTEROID; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INFLIXIMAB; ISONIAZID; MERCAPTOPURINE;

ADOLESCENT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYTOKINE RELEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; GAMMA INTERFERON RELEASE ASSAY; HUMAN; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PEDIATRIC ULCERATIVE COLITIS ACTIVITY INDEX; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TUBERCULIN TEST; ULCERATIVE COLITIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; BODY WEIGHT; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; PLATELET COUNT; RISK FACTORS; SERUM ALBUMIN; TUBERCULIN TEST;

EID: 84896723390     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000205     Document Type: Article

References (30)

1. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9
2. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-To-severe Crohn's disease in children. Gastroenterology 2007;132:863-73
3. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365.e2-74.e2
4. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:946-53
5. Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-7
6. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
7. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J 2010;36:1185-206
8. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61
9. Helwig U, Muller M, Hedderich J, et al. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohns Colitis 2012; 6:419-24
10. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol 2009; 15:2570-8
11. Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of nutrient modulation of the immune response. J Allergy Clin Immunol 2005;115:1119-28
12. Schaible UE, Kaufmann SH. Malnutrition and infection: Complex mechanisms and global impacts. PLoS Med 2007;4:e115
13. van Zyl-Smit RN, Zwerling A, Dheda K, et al.Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: A systematic review. PLoS ONE 2009;4:e8517
14. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: Current management. Gut 2006;55 (suppl 1):i16-35
15. Papay P, Primas C, Eser A, et al. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-Alpha inhibitors. Aliment Pharmacol Ther 2012;36:858-65
16. Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011;17:77-83
17. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (suppl A):5-36
18. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis-The Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1-7
19. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47
20. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology 2007;133:423-32
21. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3:47-91
22. Veereman-Wauters G, de Ridder L, Veres G, et al. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group Commentary. J Pediatr Gastroenterol Nutr 2012;54:830-7
23. Kilic O, Kasapcopur O, Camcioglu Y, et al. Is it safe to use anti-TNF-Alpha agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 2012;32:2675-9
24. Papay P, Eser A, Winkler S, et al. Predictors of indeterminate IFN-gamma release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest 2011;41:1071-6
25. Bélard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-Tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340-9
26. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferongamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799-806
27. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: A metaanalysis. Chest 2010;137:952-68
28. Harries AD, Fitzsimons E, Fifield R, et al. Platelet count: A simple measure of activity in Crohn's disease. Br Med J (Clin Res Ed) 1983; 286:1476
29. Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973;8:135-8
30. Mijac DD, Jankovic GL, Jorga J, et al. Nutritional status in patients with active inflammatory bowel disease: Prevalence of malnutrition and methods for routine nutritional assessment. Eur J Intern Med 2010; 21:315-9